Literature DB >> 19084375

Alternate-day fasting reduces global cell proliferation rates independently of dietary fat content in mice.

Krista A Varady1, Donald J Roohk, Mathew Bruss, Marc K Hellerstein.   

Abstract

OBJECTIVE: Cell proliferation rates represent a central element in the promotional phase of carcinogenesis. Modified alternate-day fasting (ADF), i.e., a partial 24-h fast alternated with 24-h ad libitum feeding, reduces global cell proliferation rates on a low-fat (LF) diet. Because the majority of Americans consume a diet that is high in fat, testing the antiproliferative ability of ADF on a high-fat (HF) diet is important in terms of diet tolerability in humans. Accordingly, we examined the effects of 85% restriction on the fast day (ADF-85%) with an LF or HF background diet on proliferation rates of various tissues.
METHODS: In a 4-wk study, male C57BL/6J mice were randomized to one of three groups: 1) ADF-85%-LF, 2) ADF-85%-HF, or 3) control.
RESULTS: Body weights of the ADF mice were similar to that of controls throughout the study. A hyperphagic response (P < 0.001) was noted only in the ADF-85%-LF group ( approximately 55% more food consumed on the feed day than controls). No differences were noted for mean energy intake between ADF groups on feed or fast days. Equivalent reductions (P < 0.01) in epidermal, prostate, liver, and splenic T-cell proliferation rates were observed in both ADF groups versus controls. Plasma insulin-like growth factor-1 levels decreased (P < 0.05) similarly in both ADF groups. Insulin-like growth factor-1 mRNA levels were not affected by either treatment.
CONCLUSION: These findings indicate that ADF has an antiproliferative effect over a wide range of fat intakes, which may enhance adherence to ADF in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084375     DOI: 10.1016/j.nut.2008.10.017

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  8 in total

1.  Intermittent Fasting Promotes Fat Loss With Lean Mass Retention, Increased Hypothalamic Norepinephrine Content, and Increased Neuropeptide Y Gene Expression in Diet-Induced Obese Male Mice.

Authors:  Juliet D Gotthardt; Jessica L Verpeut; Bryn L Yeomans; Jennifer A Yang; Ali Yasrebi; Troy A Roepke; Nicholas T Bello
Journal:  Endocrinology       Date:  2015-12-14       Impact factor: 4.736

2.  Intermittent and periodic fasting, longevity and disease.

Authors:  Valter D Longo; Maira Di Tano; Mark P Mattson; Novella Guidi
Journal:  Nat Aging       Date:  2021-01-14

Review 3.  Could Intermittent Energy Restriction and Intermittent Fasting Reduce Rates of Cancer in Obese, Overweight, and Normal-Weight Subjects? A Summary of Evidence.

Authors:  Michelle N Harvie; Tony Howell
Journal:  Adv Nutr       Date:  2016-07-15       Impact factor: 8.701

Review 4.  Employing proteomics to understand the effects of nutritional intervention in cancer treatment.

Authors:  Monica M Schroll; Amanda B Hummon
Journal:  Anal Bioanal Chem       Date:  2018-07-04       Impact factor: 4.478

Review 5.  Targeting Glucose Metabolism to Enhance Immunotherapy: Emerging Evidence on Intermittent Fasting and Calorie Restriction Mimetics.

Authors:  William J Turbitt; Wendy Demark-Wahnefried; Courtney M Peterson; Lyse A Norian
Journal:  Front Immunol       Date:  2019-06-25       Impact factor: 7.561

6.  Health Effects of Alternate Day Fasting Versus Pair-Fed Caloric Restriction in Diet-Induced Obese C57Bl/6J Male Mice.

Authors:  Chloe G Henderson; Damian L Turner; Steven J Swoap
Journal:  Front Physiol       Date:  2021-02-26       Impact factor: 4.566

Review 7.  Circadian clock synchrony and chronotherapy opportunities in cancer treatment.

Authors:  Anna R Damato; Erik D Herzog
Journal:  Semin Cell Dev Biol       Date:  2021-08-03       Impact factor: 7.499

8.  Integrative analyses of hepatic differentially expressed genes and blood biomarkers during the peripartal period between dairy cows overfed or restricted-fed energy prepartum.

Authors:  Khuram Shahzad; Massimo Bionaz; Erminio Trevisi; Giuseppe Bertoni; Sandra L Rodriguez-Zas; Juan J Loor
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.